Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

Current Neurology and Neuroscience Reports

Volumn 15, Issue 7, 2015, Pages

  Kleyman, Inna ^a   Brannagan, Thomas H ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Chronic inflammatory demyelinating polyneuropathy (CIDP); Corticosteroids; Intravenous immunoglobulin (IVIg); Plasmapheresis

Indexed keywords

ALEMTUZUMAB; ALPHA2A INTERFERON; AZATHIOPRINE; BETA1A INTERFERON; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; ETANERCEPT; FINGOLIMOD; FLUDARABINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NATALIZUMAB; PREDNISONE; RITUXIMAB; TACROLIMUS; VITAMIN D; IMMUNOSUPPRESSIVE AGENT;

ANEMIA; BLEEDING; CHEMOTHERAPY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONTROLLED CLINICAL TRIAL (TOPIC); EARLY DIAGNOSIS; FAINTNESS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; HYPOCALCEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOCYTE COUNT; LONG TERM CARE; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; NEUROLOGIC EXAMINATION; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

ADRENAL CORTEX HORMONES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; NEUROLOGIC EXAMINATION; PLASMAPHERESIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84930199161     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-015-0563-z     Document Type: Review

References (99)

1. Dyck PJ et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11(2):136–41.
2. Schimmer BP, Funder JW. Chapter 42: ACTH, adrenal steroids and pharmacology of the adrenal cortex In: Brunton LL, Bruce AC, Bjorn CK, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill; 2011. p. 12e.
3. van Schaik IN et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245–53.
4. Barohn RJ et al. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46(8):878–84.
5. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7(9):507–17.
6. Buttgereit F et al. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50(11):3408–17.
7. Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol. 2008;65(11):1460–4.
8. Eftimov F et al. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology. 2012;78(14):1079–84. Long-term follow-up data on patients from randomized controlled study comparing pulsed dexamethasone with daily prednisolone.
9. Nobile-Orazio E et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11(6):493–502. A multicenter, randomized, double-blind placebo-controlled trial comparing IVIg with intravenous methylprednisolone administered for six months.
10. Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol. 2005;62(2):249–54.
11. Börü ÜT et al. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-year follow up. Clin Neurol Neurosurg. 2014;118:89–93. A retrospective analysis of patients with CIDP treated with monthly high-dose intravenous methylprednisolone for five years showing long-term benefit after ten years of follow up.
12. Brannagan TH. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology. 2002;59.12 suppl 6:S33–40.
13. Wolberg AS et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65(1):30–4.
14. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev. 2010;236(1):265–75.
15. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011;127(2):315–23.
16. Bick S et al. Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy—a new mechanism of action? J Neuroimmunol. 2013;256(1):84–90.
17. Wakerley BR, Yuki N. Monitoring intravenous immunoglobulin dosing regimens in chronic inflammatory demyelinating polyneuropathy: search for a biomarker. J Neurol Neurosurg Psychiatry. 2013;84(8):830–83.
18. Iijima M et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology. 2005;64(8):1471–5.
19. Eftimov, F. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Library (2013).
20. Hughes RAC et al. Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–44.
21. Latov N et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67(7):802–7.
22. Querol L et al. Long-term outcome in CIDP patients treated with IVIg: a retrospective study. Muscle Nerve. 2013;48(870):6.
23. Gorson KC et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst. 2010;15(4):326–33.
24. Kuwabara S et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry. 2006;77(1):66–70.
25. Nobile-Orazio E et al. Frequency and time to relapse after therapy discontinuation in CIDP patients treated for six months with IVIG or IV methylprednisolone (IMC study follow-up)”. J Peripher Nerv Syst JNNP. 2014. doi:10.1136/jnnp-2013-307515. A long-term follow up of patients with CIDP treated with IVIg or intravenous methylprednisolone (IVMP) for six months in a randomized controlled study by Nobile-Orazio, et al. in 2012 [9]. After a median follow up of 42-43 months a similar proportion of patients in each group relapsed after discontinuing treatment with a longer median time to relapse in the IVMP group. The majority of patients (85.7 % in the IVIg group and 76.9 % in the IVMP group) required long-term treatment to maintain remission.
26. Markvardsen LH et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20(5):836–42.
27. Markvardsen LH et al. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2014;21(12):1465–70.
28. Rajabally, Yusuf A. Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects. J Neurol Neurosurg & Psychiatry. 2014;85(6):631–7.
29. Brannagan TH et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology. 1996;47(3):674–7.
30. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121(4):259–62.
31. Brecher ME. Plasma exchange: why we do what we do. J Clin Apher. 2002;17(4):207–11.
32. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher. 2000;15(1-2):74–128.
33. De Luca G et al. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1999;95(1):190–4.
34. Hahn AF et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy A double-blind, sham-controlled, cross-over study. Brain. 1996;119(4):1055–66.
35. Dyck PJ et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314(8):461–5.
36. Dyck PJ et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36(6):838–45.
37. Mehndiratta, MM, Hughes RA, and Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 3.3 (2004).
38. den Bergh V, Peter YK, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. Eur J Neurol. 2010;17(3):356–63.
39. Ho S et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996;80(3):S40–5.
40. Odaka M et al. Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry. 2005;76(8):1115–20.
41. Matsuda M et al. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci. 2004;224(1):29–35.
42. Cocito D et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011;18(12):1417–21.
43. Ahlmen, J. Positive effects of tacrolimus in a case of CIDP. Transplant Proc. 1998;30(8):4194.
44. Labate A et al. Tacrolimus-induced polyneuropathy after heart transplantation. Clin Neuropharmacol. 2010;33(3):161–2.
45. Mahdi-Rogers, M, van Doorn, PA, Hughes, RAC. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 6 (2013).
46. Brannagan TH. Current treatments of chronic immune-mediated demyelinating polyneuropathies. Muscle Nerve. 2009;39(5):563–78.
47. Good JL et al. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;51(6):1735–8.
48. Brannagan TH et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology. 2002;58(12):1856–8.
49. Gladstone DE, Prestrud AA, Brannagan TH. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2005;10(1):11–6.
50. Dyck PJ et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985;35(8):1173–73.
51. Palace J, Newsom-Davis J, Lecky BRFL. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998;50(6):1778–83.
52. Benedetti L et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve. 2004;29(5):748–9.
53. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology. 2004;63(4):715–7.
54. Bedi, G. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry. 2010;81(6):634–6.
55. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41(2):93–103.
56. Sherman WH et al. Fludarabine for IgM antibody-mediated neuropathies. Ann Neurol. 1994;36:326–7.
57. Wilson HC. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry. 1999;66(5):575–80.
58. Leitch MM, Sherman WH, Brannagan TH. Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide. Muscle Nerve. 2013;47(2):292–6.
59. Fialho D et al. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry. 2006;77(4):544–7.
60. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009;8(2):158–64.
61. Díaz‐Manera J et al. Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient. Muscle Nerve. 2009;39(3):386–8.
62. Sadnicka A et al. Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(2):230–2.
63. Münch C et al. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci. 2007;256(1):100–2.
64. Knecht H et al. Sustained remission of CIDP associated with Evans syndrome. Neurology. 2004;63(4):730–2.
65. Benedetti L et al. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle Nerve. 2008;38(2):1076–7.
66. Benedetti L et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82(3):306–8.
67. Moreau T et al. CAMPATH-1H in multiple sclerosis. Mult Scler. 1996;1(6):357–65.
68. Marsh EA et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257(6):913–9.
69. Jones JL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052.
70. Brannagan 3rd TH, Patterson SK. Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment? Expert Rev Clin Immunol. 2010;6(3):319–21.
71. Wolf C et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2010;67(7):881–3.
72. Misawa S et al. Serum levels of tumor necrosis factor-α in chronic inflammatory demyelinating polyneuropathy. Neurology. 2001;56(5):666–9.
73. Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-α expression. Pain. 1998;74(1):35–42.
74. Chin RL et al. Etanercept (Enbrel®) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2003;210(1):19–21.
75. Hamon MA et al. Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature. Rev Neurol. 2007;163(12):1232–5.
76. Lozeron P et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-α-blocker therapy. Arch Neurol. 2009;66(4):490–7.
77. Alshekhlee A et al. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-α antagonists. Muscle Nerve. 2010;41(5):723–7.
78. Choudhary PP, Thompson N, Hughes RAC. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 1995;242(4):252–3.
79. Vallat J-M et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology. 2003;60.8 suppl 3:S23–8.
80. Hadden RDM et al. Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1999;53(1):57–7.
81. Hughes RAC et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2010;74(8):651–7.
82. Matsuse D et al. Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonbeta-1b therapy in a patient with childhood-onset multiple sclerosis. Intern Med. 2005;44(1):68–72.
83. Hughes, Richard AC, Anthony V. Swan, and Pieter A. van Doorn. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Library (2004).
84. Gorson KC et al. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology. 1997;48(3):777–80.
85. Pavesi G et al. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol. 2002;249(6):777–9.
86. Erdener ŞE et al. Remission with fingolimod in a case of demyelinating polyneuropathy. Muscle Nerve. 2014;50(4):615–7.
87. Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2002;72(1):127–8.
88. Vermeulen M, Van Oers MHJ. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. J Neurol Neurosurg Psychiatry. 2007;78(10):1154–54.
89. Oyama Y et al. Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology. 2007;69(18):1802–3.
90. Axelson, HW, Gunnar Ö, Håkan A. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. BMJ Case Rep 2009 (2009): bcr0920080927.
91. Mahdi‐Rogers M et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst. 2009;14(2):118–24.
92. Remenyi P et al. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol. 2007;14(8), e1.
93. Press R et al. Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP. J Neurol Neurosurg Psychiatry. 2014;85(6):618–24.
94. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997;48(2):321–8.
95. Viala K et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(1):50–6.
96. Rabin, M. Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal. J Neurol Neurosurg & Psychiatry (2013): jnnp-2013.
97. Hughes R et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50(2):195–201.
98. Köller H et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352(13):1343–56.
99. Kissel, JT. The treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Seminars Neurol. Vol. 23. No. 2. 2003.